Aging is an inevitable process that affects even the most resilient men.
If you’re over 25 and are noticing low libido, less stamina, and some extra weight gain, you may want to check your testosterone levels.
According to the Western Michigan Urological Associates, one in every four men aged 30+ has low testosterone.
That’s the equivalent of 13 million men in the United States!
But look around, do you really think 1 in 4 is truly representative of what your eyes see?
Testosterone is the main male sex hormone crucial for fertility, muscle development, bone density, libido, and mood.
If you have insufficient testosterone levels, you may experience changes in the body such as sexual dysfunction.
In fact, 63% of men diagnosed with low testosterone report low sex drive, and 70% of them have erectile dysfunction.
Although maintaining a healthy lifestyle through exercise and nutrition can help, researchers have discovered a more holistic approach to boost your testosterone levels so you can feel normal again.
We’re talking about using peptides to boost testosterone, which can also help combat signs of aging and restore your sexual well-being.
In this article, we talk about the best testosterone-boosting peptides and explore their potential health benefits.
Why Use Peptides for Testosterone?
Peptides support the body’s natural biological processes, including the production of human growth hormone (HGH).
They also stimulate other hormones in the body that tend to decline with age, including testosterone.
Compared to other options such as testosterone optimization therapy or TRT/TOT, peptides may help boost serum testosterone levels without suppressing the natural production of testosterone or affecting fertility.
How Peptides Work to Increase Testosterone Levels
The hypothalamus and pituitary gland control the amount of testosterone being produced and released to your gonads (testicles in men and ovaries in women).
The hypothalamus releases gonadotropin-releasing hormone (GnRH) to trigger the pituitary gland to release luteinizing hormone (LH).
LH then travels to the gonads and sends a hormonal signal for them to produce and release testosterone.
As testosterone levels in the blood increase, they suppress the release of GnRH.
This feedback loop helps control and maintain normal levels of testosterone in the body.
So how can peptides help with boosting your testosterone levels?
There are three ways.
First, peptides can directly impact the hypothalamic-pituitary-adrenal (HPA) axis and stimulate testosterone synthesis.
These types of peptides support the release of hormones that play major roles in increasing serum testosterone levels, including GnRH, LH and follicle-stimulating hormone (FSH).
Second, peptides can boost growth hormone levels in the pituitary gland, increasing LH and FSH levels and thereby leads to a boost in testosterone.
Third, peptides may play a role in preventing the conversion of testosterone into estrogen, particularly in individuals with excess body fat.
When a man is fat, inflamed and or insulin resistant, high aromatization (over producing estrogen) can send a negative signal to the pituitary gland, reducing its ability to produce LH, FSH, and testosterone, instead of making more.
(NOTE: This is NOT the same thing as saying you should suppress your estrogen levels, but rather find an optimal balance that works for your hormonal individuality)
So, what peptides increase testosterone levels?
Below are 10 of the best peptides one can use to start feeling like yourself again.
The 10 Best Peptides for Increasing Testosterone
Kisspeptin-10 and gonadorelin are two peptides that stimulate testosterone synthesis by directly affecting the hypothalamic-pituitary-adrenal (HPA) axis.
Kisspeptin-10
Kisspeptin, a peptide produced by the hypothalamus in the brain, plays an important role in human reproduction and sex drive, cognitive function, bone health, and fat distribution.
It works by binding with a G-protein-coupled receptor (GPCR) and releases GnRH.
The release of GnRH helps release FSH, LH and other sexual steroids.
These hormones bind with the gonads to release both sperm and egg cells, boosting testosterone levels.
In a study published in The Journal of Clinical Endocrinology and Metabolism, healthy men who were injected with kisspeptin-10 showed an increase in LSH, FSH, and testosterone after 22.5 hours compared with those test subjects who were given a saline infusion.
The dose response of kisspeptin-10 was investigated by administering iv bolus doses (0.01–3.0 μg/kg) and vehicle to healthy men.
Effects on LH pulse frequency and size were determined by deconvolution analysis during infusion of kisspeptin-10 for up to 22.5 h.
Intravenous bolus kisspeptin-10 resulted in a rapid and dose-dependent rise in serum LH concentration, with maximal stimulation at 1 μg/kg (4.1 ± 0.4 to 12.4 ± 1.7 IU/liter at 30 min, P < 0.001, n = 6). Administration of 3 μg/kg elicited a reduced response vs. 1 μg/kg (P < 0.05).
Infusion of kisspeptin-10 at 4 μg/kg · h for 22.5 h elicited an increase in LH from a mean of 5.4 ± 0.7 to 20.8 ± 4.9 IU/liter (n = 4; P < 0.05) and serum testosterone increased from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter (P < 0.001).
LH pulses were obscured at this high rate of secretion, but a lower dose infusion of kisspeptin-10 (1.5 μg/kg · h) increased mean LH from 5.2 ± 0.8 to 14.1 ± 1.7 IU/liter (n = 4; P < 0.01) and increased LH pulse frequency from 0.7 ± 0.1 to 1.0 ± 0.2 pulses/h (P < 0.05) and secretory burst mass from 3.9 ± 0.4 to 12.8 ± 2.6 IU/liter (P < 0.05).
Gonadorelin
Gonadorelin, or gonadorelin acetate,is a synthetic peptide produced in a region of the brain that mimics natural GnRH.
It stimulates the release of LH and FSH from the anterior pituitary gland, which helps with delayed puberty, infertility, and the absence of menstruation.
In women, this helps boost egg production in the ovaries, assisting with regular ovulation while increasing the chance of getting pregnant.
In men, Gonadorelin boosts sperm production and testosterone.
It also helps men minimize the risk of testicular atrophy (i.e. the shrinking of their testicles).
This has been backed by a study in the Asian Journal of Andrology, where men with testosterone deficiency who were given gonadorelin were able to restore their sperm production.
Human chorionic gonadotropin (hCG) is a naturally occurring protein produced by the human placenta with a serum half-life of approximately 36 h.
Structurally, hCG shares an identical α-subunit with LH and FSH. However, hCG has a unique β-subunit that is virtually identical to the LH β-subunit except that it has an additional 24 amino acid tail at the amino terminus of the protein, which is highly glycosylated and leads to both a longer circulating half-life of hCG (~36 h) versus LH (~30 min) and increased receptor activity.
Clinically, hCG has proven successful at inducing and/or maintaining spermatogenesis alone or in combination with FSH in patients with hypogonadotropic hypogonadism (HH).
HH is an uncommon but treatable cause of male factor infertility classically considered secondary to pathology of the hypothalamus or pituitary gland as seen with Kallman’s syndrome, Prader–Willi syndrome, panhypopituitarism from prolactinomas, tumors, infection or radiation, or idiopathic causes.
Recently, recognition that the increasingly common use of exogenous TRT and/or AAS can also induce HH, also known as ASIH, with associated diminished spermatogenesis.
Therefore, men with azoospermia or severe spermatogenic defects due to classic HH serves as a useful context in whom to appreciate the effect of gonadotropins upon spermatogenesis clinically.
Moreover, infertile men who were given nasal administration of gonadorelin for a year had increased testosterone levels and sperm production, according to a study published in the Journal of Fertility and Sterility.
The patient’s laboratory examination showed low serum levels of gonadotropins and testosterone.
After being diagnosed with hypogonadotropic hypogonadism, 15 μg of buserelin acetate spray was administrated in each nostril three times a day (total: 90 μg/day).
This therapy improved semen parameters and serum gonadotropin and testosterone levels.
After approximately 1 year of this treatment, the patient’s serum gonadotropin and testosterone levels remained in the normal range and semen analysis showed normozoospermia.
The patient and his wife were treated with intracytoplasmic sperm injection, resulting in pregnancy.
This goes to show that a low dose of gonadorelin nasal spray can be an effective therapeutic option for patients with hypogonadism.
Below are some of the top peptides that help boost growth hormone levels in the pituitary gland, which in turn increase LH and FSH levels and thereby boost testosterone.
Sermorelin
Sermorelin acetate, also simply known as sermorelin, is a growth hormone-releasing hormone (GHRH) that’s commonly used as a treatment in children with growth hormone deficiency.
This peptide, which consists of the 29 amino acids of GHRH, helps increase both FSH and LH levels in kids.
In fact, kids with pulsatile GH secretion who were given 1 mg of sermorelin not only had boosted growth hormone and insulin growth factor 1 levels, but also triggered the release of FSH and LH — two hormones that produce testosterone.
We administered two different growth hormone-releasing hormones (GHRH) to 20 short, prepubertal children who had spontaneous secretion of growth hormone (GH), assessed from 24-hour GH secretion profiles (72 sampling periods of 20 min).
We compared one i.v. injection of 1 microgram/kg of GHRH 1-40 with that of GHRH 1-29 regarding serum concentrations of GH, prolactin, luteinizing hormone, follicle-stimulating hormone and IGF-I.
The children were allocated to two groups without statistical randomization. Both groups were given both peptides, with at least 1 week in between.
The first group started with GHRH 1-40, the other with GHRH 1-29. The peptides both induced an increased serum concentration of GH of the same magnitude: mean maximal peak of 89 +/- 12 mU/l after GHRH 1-40 and 94 +/- 10 mU/l after GHRH 1-29 (n.s.).
The mean difference in maximum serum GH concentration in each child after injection was 52 +/- 9 mU/l, range 1-153 mU/l.
GHRH 1-29 also induced a short-term, small increase in the concentrations of prolactin (p less than 0.05), luteinizing hormone (p less than 0.01) and follicle-stimulating hormone (p less than 0.05).
We conclude that the shorter sequence GHRH 1-29, when given in a dose of 1 microgram/kg, gives a rise in serum concentration of GH similar to that after the native form GHRH 1-40.
In another study published in the Journal of Endocrinology, GH-deficient rats had increased testosterone levels after 7 days of sermorelin treatment.
It also helped to treat delayed puberty that was due to GH deficiency.
To test the hypothesis that insulin-like growth factor (IGF-I) is required for the in vivo development of testicular Leydig cell function, either recombinant human GH [(hGH) (1.5 micrograms/g BW) or recombinant IGF-I (1 microgram/g BW) was injected three times daily into immature Snell dwarf mice (dw/dw) and into phenotypically normal control (Dw/-) for 7 days.
In dw/dw mice hGH enhanced significantly body, liver, kidney, and testicular weight.
In addition, hGH increased testicular LH receptors and the acute steroidogenic response to human CG, but there was no significant effect on basal plasma testosterone or plasma LH levels.
The effects of IGF-I in body and kidney weight were less pronounced than those produced by hGH, but its effects on testicular weight and LH receptors, as well as on the acute steroidogenic response to human CG, were similar to that observed after hGH treatment.
In Dw/- mice hGH had no effect on either body or organ weight or on testicular function, despite the fact that it induced a significant increase in plasma IGF-I levels.
These results indicated that IGF-I is able to induce the maturation of Leydig cell function and that the effects of hGH on the testis are probably mediated by IGF-I.
They also suggest that the delayed puberty associated with GH deficiency or resistance is most likely related to an IGF-I deficiency.
Ipamorelin
Ipamorelin is also a synthetic growth hormone-releasing peptide (GHRP) that stimulates the release of growth hormone (GH) through the pituitary gland.
By boosting GH secretion, the peptide ipamorelin indirectly increases testosterone levels by encouraging the release of LH from the pituitary gland.
This may lead to improved sexual function, increased libido, and a stronger desire for one’s partner.
This was reported by Japanese researchers in rats that saw increased testosterone levels after ipamorelin administration.
The modulatory effect of GH on basal, LH and T3 mediated secretion of testosterone and oestradiol by purified rat (60 day old) Leydig cells was studied in vitro.
Percoll gradient purified Leydig cells (1×103) were cultured for 48 hours at 34°C in a medium containing different concentrations of rat GH (5-400ng/mL), after an initial culture for 24 hours at 37°C.
GH increased testosterone and oestradiol secretions in a dose dependent manner.
While testosterone secretion reached the saturation point with 50ng GH, oestradiol secretion reached the saturation point with 150ng GH, followed by diminished secretions.
Co-administration of minimum (10ng) effective does of GH with minimum (25ng) or maximum (100ng) effective doses of oLH significantly decreased the testosterone secretion.
However, an increased secretion of testosterone was observed when maximum effective doses of rGH (50ng) and oLH (100ng) were co-administered.
Minimum effective (25ng) or maximum effective (50ng) doses of T3 inhibited GH mediated secretion of testosterone in vitro.
Oestradiol concentration in the culture medium increased when either dose of rGH was co-administered with the minimum or maximum effective doses of oLH. T3 50ng augmented the secretion of oestradiol by Leydig cells in the presence of GH.
CJC-1295
CJC-1295 can also help ramp up sexual power thanks to its ability to stimulate the pituitary gland to release testosterone, estrogen, and other hormones involved in the regulation of the sex drive.
By increasing levels of growth hormone and insulin-like growth factor 1 (IGF-1), CJC 1295 can help improve sex drive in both men and women.
This is backed by a study published in The Journal of Clinical Endocrinology & Metabolism, where men and women given GH, like CJC-1295, had improved sex drive and testosterone levels.
We undertook a study of the separate and combined effects of age and sex on the pulsatile pattern of GH secretion.
The 24-h secretory profile of GH was generated by 20-min sampling in 10 young women (aged 18–33 yr), 10 young men (aged 18–33 yr), 8 postmenopausal women (aged >55 yr), and 8 older men (aged >55 yr).
A computer-assisted pulse analysis program was used to assess both total GH secretion, as reflected in the 24-h integrated GH concentration (IGHC), and pulsatile secretion, as denoted by pulse frequency, duration, amplitude, and the fraction of GH secreted in pulses during the 24-h period (FGHP).
IGHC was significantly greater in women than in men (P < 0.025) and greater in the young than in the old (P < 0.003).
The mean pulse amplitude, duration, and FGHP were each greater in the young (P < 0.006, P < 0.03, and P < 0.0001, respectively), but not significantly different between the sexes.
The mean pulse frequency was not affected by sex or age.
The serum concentration of free estradiol, but not free testosterone, correlated with IGHC (r = 0.46; P < 0.005), pulse amplitude (r = 0.53; P < 0.001), and FGHP (r = 0.59; P < 0.0002).
After correcting for the effects of estradiol, neither sex nor age influenced IGHC or mean pulse amplitude, while the effect of age on FGHP was reduced from 81% to 29%. Of the indices of GH secretion, FGHP had the strongest correlation (r = 0.43; P < 0.006) with somatomedin-C.
Somatomedin-C declined significantly with age in both sexes.
Our results indicate that sex and age have independent and interrelated effects on GH secretion. These effects can be largely accounted for by corresponding variations in endogenous estra-diol levels.
GHRP-6
GHRP-6, or Growth Hormone-Releasing Peptide 6, is another peptide that may support healthy testosterone levels by stimulating the pituitary gland to release LH
Consequently, this sends signals to the testes to produce more testosterone.
In a study published in the AIP Conference Proceedings, white rabbits with gonadal dysfunction given the peptide GHRP-6 had increased testosterone levels.
The present study was conducted to diagnose the ability of growth hormone-releasing peptide (GHRP-6) or growth hormone-secreting factors (GHS) secretagogues to treat gonadal dysfunction caused mainly by low testosterone levels induced by the anabolic steroid drug oxymetholone and then evaluate growth hormone(GH), testosterone levels, in addition, to evaluate its effect to hormone levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), Prolactin Hormone (PRL) and Estradiol (E2) and all of which were estimated in the sera of white rabbits.
The study design was divided into 4 groups (3 treatment groups each containing 11 rabbits+a control group (as a control sample).
Then the blood was taken and the sera separated after the end of the prescribed dose and injection period for each group, The results of the analysis are as follows:
There were no significant differences in the levels of growth hormone (GH) for the G1 group, while showed a significant increase in the groups of G2, G3, and this increase was higher for a group of G2 than for G3.
The results showed a significant decrease in the testosterone levels of the G1 group, and a significant increase in its levels for the G2 group, while no significant differences were observed for the G3 group, and the results also showed a significant decrease in the levels of the luteinizing hormone (LH) of the G1 group and a significant increase in its levels for the G2 group while no significant differences were observed for the G3 group, as well as the results showed no significant difference in the follicle stimulating hormone (FSH) levels of the G1 and G2 groups, and it showed a significant increase in its levels in the G3 group, with respect to prolactin (PRL)
The results showed a significant increase in the G1 group, and the G2, G3 groups did not show any significant differences, estradiol(E2) showed a significant increase in its levels in the G1 ,G2 groups, and no significant differences in its levels in the G3 group, noting that all the results mentioned above were compared with the control group C.
GHRP-2
GHRP-2, or Growth Hormone-Releasing Peptide 2, works similarly to GHRP-6.
Both peptides act on the hypothalamus to stimulate the natural release of GHRH, boosting levels of LH and testosterone.
But unlike GHRP-6, GHRP-2 is more potent at stimulating growth hormone release.
In an Oxford study, researchers aimed to discover the effects of GHRP-2 on hypogonadism, hypothyroidism, and central hyposomatotropism.
Following just 5 days of treatment, men who received GHRP-2 alongside TRH and GnRH experienced an impressive 80% increase in testosterone levels from day 1 to day 3.
Thirty-three men with prolonged critical illness participated at baseline compared to 50 age- and body mass index (BMI)-matched controls.
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Patients revealed suppressed pulsatile GH, TSH and LH secretion in the face of low serum concentrations of IGF-I, IGFBP-3 and the acid-labile subunit (ALS) (P < 0.0001 each), thyroid hormones (P < 0.0001) and total and estimated free testosterone (P < 0.0001) levels, whereas free oestradiol (E2) estimates were normal.
Serum dehydroepiandrosterone sulphate (DHEAS) levels were also suppressed whereas morning cortisol was normal.
Serum levels of type I procollagen (PICP) and bone alkaline phosphatase (sALP) were elevated whereas osteocalcin (OC) was low (P = 0.03).
Ureagenesis (P < 0.0001) and breakdown of bone tissue (P < 0.0001) were increased. Baseline serum TNF-alpha, IL-6 and C-reactive protein level and white blood cell (WBC) count were elevated; serum lactate was normal.
Only low T4 and high IGFBP-1 levels independently predicted mortality.
GHRP-2 infusion reactivated GH secretion and normalized serum IGF-I, IGFBP-3 and ALS.
GHRP-2 + TRH infusion reactivated both the GH axis and the thyroid axis, with normal levels of T4 and T3 reached within 1 day.
Only GHRP-2 + TRH infusion combined with GnRH pulses reactivated the GH and TSH axis and at the same time increased pulsatile LH secretion compared to placebo.
Only GnRH pulses together with GHRP-2 + TRH infusion increased testosterone significantly from day 2 (peak increase of + 312%) through day 5 and serum E2 with > 80% from day 1 through day 3 (all P = 0.05).
Ureagenesis was reduced by GHRP-2 + TRH + GnRH (P = 0.01) and by GHRP-2 + TRH (P = 0.009) but not by GHRP-2 alone. Serum OC levels were increased only by GHRP-2 + TRH + GnRH (P = 0.03), with a trend for GHRP-2 + TRH (P = 0.09), but not by GHRP-2 alone.
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
MK677
MK-677, also known as ibutamoren or ibutamoren mesylate, is a growth hormone secretagogue that increases growth hormone production and insulin-like growth factor 1 (IGF-1).
The ability of MK-677 to boost GH and IGF-1 levels is associated with many health benefits, including improving sex drive and sexual function.
It helps boost libido by increasing testosterone levels in men and estrogen in women, as proven in a study published in the Endocrine Journal.
The modulatory effect of GH on basal, LH and T3 mediated secretion of testosterone and oestradiol by purified rat (60 day old) Leydig cells was studied in vitro. Percoll gradient purified Leydig cells (1×103) were cultured for 48 hours at 34°C in a medium containing different concentrations of rat GH (5-400ng/mL), after an initial culture for 24 hours at 37°C.
GH increased testosterone and oestradiol secretions in a dose dependent manner.
While testosterone secretion reached the saturation point with 50ng GH, oestradiol secretion reached the saturation point with 150ng GH, followed by diminished secretions.
Co-administration of minimum (10ng) effective does of GH with minimum (25ng) or maximum (100ng) effective doses of oLH significantly decreased the testosterone secretion.
However, an increased secretion of testosterone was observed when maximum effective doses of rGH (50ng) and oLH (100ng) were co-administered.
Minimum effective (25ng) or maximum effective (50ng) doses of T3 inhibited GH mediated secretion of testosterone in vitro. Oestradiol concentration in the culture medium increased when either dose of rGH was co-administered with the minimum or maximum effective doses of oLH.
T3 50ng augmented the secretion of oestradiol by Leydig cells in the presence of GH. These results indicate that GH acts as a gonadotrophin to stimulate testosterone and oestradiol secretions by Leydig cells, and that it modulates LH or T3 induced secretion of these steroids, depending on the intensity of their stimulation.
Lastly, the following peptides help you lose body fat and therefore minimize your risk of testosterone converting into estrogen.
AOD-9604
Anti-Obesity Drug-9604, also known as AOD 9604 or AOD-9604, is a synthetic analog of HGH.
This peptide, developed by a Melbourne-based biotechnology company, has been shown to promote weight loss with little to no side effects commonly seen in existing obesity drugs.
It helps people with obesity lose body fat by stimulating the pituitary gland and speeding up the body’s metabolism for faster weight loss.
This fat-burning process is called lipolysis, meaning it breaks down fats stored in fat cells.
You see, being overweight can increase the risk of testosterone aromatization.
The enzyme aromatase, found in the adipose tissue, converts testosterone to estrogen.
This increased estrogen can trigger a negative feedback loop, suppressing the HPG axis and reducing testosterone levels.
In fact, 300 obese patients who were given the peptide AOD-9604 for 12 weeks lost 2.8 kilograms compared to the placebo group.
The drug – codenamed AOD9604 – was taken orally once daily by 300 obese patients at five trial sites over a 12-week period.
Six doses were used – 0 mg (placebo), 1mg, 5 mg, 10 mg, 20 mg and 30 mg.
The group receiving the 1mg dose lost the most weight, averaging a weight loss over the 12 weeks of 2.8 kilograms, more than triple the weight lost by those on placebo, who lost an average of 0.8 kilograms.
The rate of weight loss was maintained throughout the treatment period, an encouraging trend for expectations of longer-term dosing.
The weight lost by the 1mg group was slightly more than that achieved by the world’s largest selling prescription obesity medication in similar trials over the same period, without its troublesome side effects.
The trial results also demonstrated a small but consistent improvement in cholesterol profiles, and a reduction in the number of patients with impaired glucose tolerance.
Tesamorelin
Tesamorelin is an FDA-approved peptide for lipodystrophy or abnormal distribution of fat in the body.
This peptide is a synthetic analog of growth hormone-releasing factor, which stimulates the pituitary gland to secrete growth hormone, boosting insulin-like growth factor (IGF-1) levels.
This process then stimulates fat loss, which helps inhibit testosterone from converting to estrogen.
In a study with 412 HIV patients with an accumulation of abdominal fat, those who were given 2 mg of tesamorelin for 26 weeks saw their visceral fat decrease by 15.2% compared to the placebo group, who saw an increase of 5% fat.
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
The measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group; the levels of triglycerides decreased by 50 mg per deciliter and increased by 9 mg per deciliter, respectively, and the ratio of total cholesterol to HDL cholesterol decreased by 0.31 and increased by 0.21, respectively (P<0.001 for all comparisons).
Levels of total cholesterol and HDL cholesterol also improved significantly in the tesamorelin group.
Levels of IGF-I increased by 81.0% in the tesamorelin group and decreased by 5.0% in the placebo group (P<0.001).
Adverse events did not differ significantly between the two study groups, but more patients in the tesamorelin group withdrew from the study because of an adverse event.
Peptide Therapy vs Testosterone Optimization Therapy
Testosterone optimization therapy (TOT/TRT) is a treatment that aims to boost androgen levels in men and manage low testosterone symptoms.
This includes administering testosterone to increase serum free Testosterone levels.
The *problem* with TRT is it can suppress natural testosterone synthesis and testicular function.
This may lead to infertility and testicular atrophy over time (as a Jay Campbell informed reader, you KNOW this can be easily addressed through modalities like hCG).
Peptide therapy, on the other hand, may help increase endogenous (natty) testosterone levels within a healthy range.
Unlike testosterone optimization therapy, peptides are likely to not suppress the body’s natural production of testosterone or affect fertility.
(NOTE: Testosterone optimization therapy will always reign as the supreme option aka biggest tool in the tool belt especially in our toxic modernized environment for optimizing male and female testosterone level …
Peptide testosterone enhancement therapies *may* increase TOTAL testosterone levels to within a normal range.
However, this does not guarantee resolution of low testosterone symptoms as FREE testosterone dictates how much of it is bioavailable.
For that reason, peptides should be seen as supplemental and never as a replacement option for pharma-grade therapeutic testosterone administered via transdermal scrotal application or via subcutaneous or intramuscular injection)
Side Effects and Risks
Both peptide therapy and testosterone optimization therapy can help boost your testosterone levels in order to grow muscle, boost libido, and help you lose body fat.
If you’re undertaking testosterone optimization therapy for the first time, some of the common injection side effects you may experience are rash, itching, or irritation.
But as explained in The TOT Bible, you won’t have to worry about things like sleep apnea, cardiovascular problems or “excessive red blood cell production” as those myths have been thoroughly debunked.
Peptide therapy, when taken as prescribed, is generally safe.
When you first start using peptides to boost testosterone, you might notice some mild side effects that usually go away on their own.
Some of these include allergic reactions such as swelling and hives, hormonal imbalance, headaches, and nausea.
As long as you administer peptides at the correct dosage and frequency, you shouldn’t have anything to worry about.
Both peptides and testosterone therapy can interact with other medications, so always consult an experiential-based physician to ensure you’re using either modality the right way.
And make sure to practice a fully optimized lifestyle, which includes eating an insulin-controlled diet, performing both resistance and cardio vascular exercise, and getting enough rest at night.
Where to Find Peptides for Boosting Testosterone
Still thinking about peptides for increasing your testosterone?
They can be a game-changer for managing age-related hormonal changes, especially when used alongside peptides that can help boost muscle growth and amp up your energy levels.
But here’s the thing – they’re not a quick fix for everyone, and DEFINITELY not a replacement for testosterone optimization therapy.
Some peptides may put you at risk of side effects that may negatively affect your health if you don’t know what you’re doing.
Therefore, before you jump in, make sure to talk with your doctor to help you decide which of the peptides featured in this article are best for you.
If you’re looking for the best peptides for boosting testosterone, you can check out Limitless Life Nootropics, the industry’s only source for third-party-tested products.
They have some of the best formulations of testosterone-boosting peptides such as ipamorelin, CJC-1295, kisspeptin, MK-677, and AOD 9604, on the market.
Plus, Limitless offers the BEST deals on both price and peptide purity.
Use code JAY15 at the checkout cart for 15% off!
But before you start injecting these peptides into your body recklessly, make sure you first read the Top 10 Mistakes People Make When Starting Therapeutic Peptides FREE PDF!
Seriously, this short e-book will save you a lot of wasted money and poorly spent time (not to mention preventing you from potential self-inflicted injuries).
And the emails I’ll send you after downloading the book contain an EXCLUSIVE 33% OFF code for my Peptides Demystified Course, so don’t miss out!
Raise Your Vibration To Optimize Your Love Creation!
PS — Want to boost your testosterone levels?
Join me and hundreds of other male and female biohackers in The Fully Optimized Health Private Membership Group to learn how you can use peptides to boost testosterone and optimize your health in your 30s and beyond.
We’re excited to discuss biohacking, health, and life optimization through peptide therapy with you.
See you on the other side!
